EZH2 and Buschke-Ollendorff syndrome: Given the critical roles of inflammatory reactions in the acute phase and immune rejection in the chronic phase in triggering BOS formation [13], we hypothesized that inhibiting EZH2 could comprehensively control these reactions and suppress BOS.